The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Advances in first-line NSCLC treatments
John Conibear, MBBCh, BSc, MSc, MRCP, FRCR, Nottingham City Hospital, Nottingham, UK, discusses first-line treatment of patients with non-small cell lung cancer (NSCLC). In patients with advanced metastatic EGFR mutations, targeted therapies such as osimertinib, and osimertinib-chemotherapy combination therapies, assessed in the FLAURA (NCT02296125) and FLAURA2 (NCT04035486) trials, have altered the standard of care in the first-line. Investigation into patient suitability, and the use of radiosurgery for intercranial disease progression during therapy, is ongoing. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
